Sanofi Stock Euronext Paris
Stocks
SANNV
FR0014013QA3
Pharmaceuticals
OTC Markets Traded
| Market Cap | 88.02B 101B 81.14B 76.32B 143B 9,521B 144B 965B 375B 4,692B 379B 371B 16,263B | P/E 2026 * |
10.9x | P/E 2027 * | 10.2x |
|---|---|---|---|---|---|
| Enterprise Value | 98.83B 113B 91.1B 85.69B 160B 10,690B 161B 1,084B 421B 5,268B 426B 417B 18,259B | EV / Sales 2026 * |
2.1x | EV / Sales 2027 * | 1.92x |
| Free-Float |
89% | Yield 2026 * |
5.8% | Yield 2027 * | 6.15% |
Last Transcript: Sanofi
| 1 day | +6.12% | ||
| 3 months | -5.71% |
| Current year | 72.56 |  | 82.72 |
| 1 year | 72.56 | | 82.72 |
| 3 years | 72.56 | | 82.72 |
| 5 years | 72.56 | | 82.72 |
| 10 years | 72.56 | | 82.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 64 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +6.12% | -.--% | - | - | 104B | |
| -1.21% | -5.37% | +39.94% | +145.38% | 992B | |
| -2.48% | -4.17% | +51.52% | +39.07% | 564B | |
| -2.14% | -3.68% | +16.71% | +56.15% | 391B | |
| -1.18% | +0.25% | +25.86% | +16.53% | 330B | |
| -2.36% | -3.12% | +24.71% | +11.59% | 280B | |
| -2.45% | -2.88% | +24.29% | +30.06% | 279B | |
| -1.91% | -0.87% | -41.95% | -49.25% | 196B | |
| -1.19% | -4.65% | +16.56% | +47.00% | 184B | |
| -1.35% | -1.68% | +14.59% | +56.94% | 156B | |
| Average | -1.02% | -1.98% | +19.14% | +39.27% | 374.58B | |
| Weighted average by Cap. | -1.54% | -2.88% | +28.03% | +63.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.07B 54.02B 43.39B 40.81B 76.35B 5,091B 76.89B 516B 200B 2,509B 203B 198B 8,696B | 49.98B 57.36B 46.07B 43.34B 81.07B 5,406B 81.64B 548B 213B 2,664B 215B 211B 9,234B |
| Net income | 8.15B 9.35B 7.51B 7.06B 13.21B 881B 13.31B 89.33B 34.69B 434B 35.09B 34.34B 1,505B | 8.95B 10.28B 8.25B 7.76B 14.53B 969B 14.63B 98.21B 38.14B 477B 38.58B 37.75B 1,654B |
| Net Debt | 10.8B 12.4B 9.96B 9.37B 17.52B 1,169B 17.65B 118B 46.01B 576B 46.54B 45.54B 1,996B | 8.08B 9.28B 7.45B 7.01B 13.11B 874B 13.2B 88.65B 34.43B 431B 34.82B 34.08B 1,493B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
